Ultra-endurance sports are increasing rapidly in popularity, with recent exponential growth in the amount of events and athlete participation. These events are characterised by long distances (>26.2 miles) that frequently span wilderness and desert environments over multiple days. While many participants are treated for minor injuries such as blisters, sprains, tendonitis and contusions, some develop more serious ailments like hyponatraemia and rhabdomyolysis. The extreme nature of these events combined with their rapidly growing participation creates the potential for increased analgesic use, as compared with marathon and half-marathon participants, seemingly favouring non-steroidal anti-inflammatory drug (NSAID) consumption.

In all classes of athletes, NSAIDs are one of the most commonly used medications for the treatment of musculoskeletal pain and inflammation. In addition to injury treatment, NSAID usage is high as a prophylactic treatment for anticipated pain, as well as to enhance the recovery of injuries sustained during an athletic event. While NSAIDs are a staple medication for the treatment of certain sports injuries, there is evidence to suggest that many athletes are consuming these medications without adequate knowledge of their intended uses or side-effects. Further, there is the potential for athletes to use NSAIDs in dosages exceeding the recommended amount.

The most popular NSAIDs exert their effects through systemic cyclooxygenase (COX) inhibition, thereby reducing the amount of inflammation-causing prostaglandins produced by the body. These effects are not limited to the site of injury and may be detrimental to the healing process of injuries involving bones and tendons. They may also cause potentially dangerous side-effects in the gastrointestinal (GI) tract and kidneys. With such a wide catalogue of potential side-effects, it is important to examine the frequency of their use, particularly in ultra-endurance competitors and how they compare with traditional marathon runners (≤26.2 miles).

Numerous studies have focused on the incidence of NSAID use during endurance athlete training and competition; however, to our knowledge, no study has investigated NSAID and analgesic consumption at multiple timings (training, competition and recovery) at a single event. The aims of this study were: (i) to evaluate and compare the prevalence of NSAID and other analgesic use during the training, competition and recovery phases of an endurance race in two cohorts (ultra-endurance runners and marathon runners); and (ii) to examine whether participants in both cohorts used NSAIDs in accordance with the recommended dose or in excess thereof.

### Methods

#### Participants

Runners at two different endurance events, the 2011 Desert Race Across the Sand (RATS) and the 2011 Empire State Marathon (ESM)
were surveyed to evaluate their patterns of NSAID and analgesic use during training for an event, during a competition, and during recovery following an event. The Desert RATS is a 148-mile ultra-endurance run, performed over six days in individual stages of 9 - 50 miles per stage, across mountainous and desert terrain in Colorado and Utah, USA. In contrast, the ESM is a more typical endurance event with runners participating in a full-marathon, half-marathon, and relays of 6 - 7 miles per runner. The ESM is held in central New York State annually. To the authors’ knowledge, no respondent participated in both events.

Data collection
Data were collected via an anonymous and voluntary survey reviewed and deemed exempt by the institutional internal review board (239319-1). The survey (Table 1) was distributed to runners during race registration at both endurance events.

Statistical analysis
Using MedCalc (version 11.6.1), data were analysed for differences of proportions between runners’ use of analgesia during training, competition and recovery, between those participating in the Desert RATS and ESM races.

Results
Seventy-three runners participated in the study: 27 ultramarathon runners from the Desert RATS and 46 marathon, half-marathon and relay runners from the ESM.

NSAIDs were the most commonly reported analgesics used at both races. Fig. 1 shows a comparison of NSAID use delineated by reported habits of using the recommended or greater-than-recommended dose. Runners in the ESM were more likely than those in the Desert RATS race (70% v. 26%, respectively) to use NSAIDs during a competition (χ²=11.76; p<0.001). There were no statistical differences in use of NSAIDs between runners participating in the Desert RATS race when compared with those participating in the ESM, during training and recovery.

In both races, acetaminophen was the next most commonly reported analgesic used, followed by topical diclofenac. The percentages of runners utilising these methods of analgesia for both race groups are shown in Table 2. Aspirin was not used by any participant who ran in the Desert RATS race, but was used by one participant who ran in the ESM. Narcotic-based medication was reportedly used by only runner of each race group and only during their respective recoveries.

Table 1. Survey distributed to runners during event registration
1. Which of these do you use either occasionally or regularly during a race to help with pain and inflammation (please select all that apply):
   - Acetaminophen (Tylenol or other)
     - Do you take more than the recommended dose? Yes/No
   - Ibuprofen (Motrin, Advil or other)
     - Do you take more than the recommended dose? Yes/No
   - Narcotic-based medication (Lortab, Percocet, hydrocodone, oxycodone or other)
     - Do you take more than the recommended dose? Yes/No
   - Aspirin (Bayer or other)
     - Do you take more than the recommended dose? Yes/No
   - Topical agent (Voltaren, Diclofenac or other)
     - Do you take more than the recommended dose? Yes/No

2. Which of these do you use either occasionally or regularly during recovery to help with pain and inflammation (please select all that apply):
   - Acetaminophen (Tylenol or other)
     - Do you take more than the recommended dose? Yes/No
   - Ibuprofen (Motrin, Advil or other)
     - Do you take more than the recommended dose? Yes/No
   - Narcotic-based medication (Lortab, Percocet, hydrocodone, oxycodone or other)
     - Do you take more than the recommended dose? Yes/No
   - Aspirin (Bayer or other)
     - Do you take more than the recommended dose? Yes/No
   - Topical agent (Voltaren, diclofenac or other)
     - Do you take more than the recommended dose? Yes/No

Discussion
When comparing the prevalence of NSAID use between ultradistance runners and marathon runners, participants reported comparable usage during training (59% v.
63%) and during recovery (59% v. 61%), but with a large discrepancy of usage during a race (70% v. 26%). These results do not suggest that more ultradistance runners use NSAIDs during training or recovery than traditional marathon runners. The similarity in training and recovery NSAID use is expected, given that both types of events would require relatively homogenous preparation and recuperation routines. Additionally, this similarity could be used as a basis for comparison between the two participants, highlighting the major difference between the two cohorts: the elevated number of NSAID users in the ultradistance event. This difference could be rationalised by the increased duration and intensity of ultradistance events, as compared with marathons, increasing the probability that an athlete may experience pain and turn to NSAIDs.

Prophylactic use of NSAIDs is common in endurance events[5,10,12,16] with 59% of Ironman Brazil triathletes reporting consumption in the three months preceding the event[5] a number comparable with this study where 59% of ultramarathon runners and 63% of marathon runners reported using NSAIDs during training. In addition, as compared with gastrointestinal and renal side-effects, prophylactic NSAID use may impede collagen synthesis and reduce tissue adaptation, predisposing the athlete to future injury.[10] Additionally, many believe that the analgesic effect of NSAIDs can mask the pain of an injury and thus prevent the athlete from resting enough to allow for proper healing.[12]

High levels of NSAID use during endurance events are fairly common, with self-reported usage ranging from 30% at the Ironman New Zealand Ultramarathon Triathlon[14] to 61% at the 2002 Boston Marathon.[6] A study of 500 runners in two major North American ultramarathons showed that 60.5% of race finishers used NSAIDs during the race and only 28.7% of finishers did not use any medication at all,[31] and our survey reaffirms this difference. However, the significantly higher rate of NSAID consumption during a race by the ultradistance cohort v. the marathon cohort is concerning, and may put the former group at an elevated risk for adverse events.

Two major risks of NSAID use during an ultra-endurance race are the development of renal complications and exercise-associated hyponatraemia (EAH). NSAIDs reduce prostaglandin synthesis in the kidney, decreasing the glomerular filtration rate and afferent renal blood flow, which may already be lowered from exercise by as much as 50%.[10–17] This combination can impair the athlete's free water clearance, increasing the risk for developing renal disease and/or EAH.[15,17,21] The National Kidney Foundation estimates that 10% of kidney failure is associated with NSAID overdose.[15] While there are many studies that demonstrate a link between NSAID use and increased renal complications in athletes,[11,17–20] other studies show that no such correlation exists.[32] However, there is consensus that NSAIDs are a clear risk factor for renal disease and EAH, and it is recommended that these drugs are avoided by endurance athletes, particularly in the wilderness ultramarathon setting.[21,22]

An additional risk factor for NSAID-related adverse events is taking more than the recommended dose. This study did not find any significant difference between NSAID-using ultradistance runners and marathon runners with regards to surpassing the recommended dose in the period during training (31% v. 14%), a race (21% v. 25%) and recovery (19% v. 25%), respectively. These results do not suggest that ultra-distance runners are at an increased risk from taking NSAIDs above the recommended dose, but only as compared with marathon runners. A potential future study could look to determine and compare the amount by which each cohort exceeds the recommended dose.

As attested to by its common use reported in this survey, acetaminophen may be a better alternative to NSAIDs for minor pain reduction, due to its milder effect on the GI tract, kidneys, and tissue regeneration.[12,14,20] Acetaminophen's main adverse effects come from overdose-induced hepatic toxicity, and some evidence suggests that its pain-relieving properties may be comparable to those of NSAIDs.[13] Topical agents (such as diclofenac) are another group of analogues used by athletes, albeit in reduced numbers (19% of ultramarathon runners during training in this study). The subcutaneous delivery to a localised site of injury makes these agents effective at treating minor acute musculoskeletal pain,[12,14,15,20,23] while avoiding many of the severe adverse reactions that NSAIDs carry.[14,20]

Encouragingly, an unpublished survey by one co-author found that 59% of athletes surveyed would modify the frequency of their NSAID use if they were better educated on their potentially harmful effects. This represents an opportunity for medical providers involved in this sport's industry to improve the health and safety of endurance race participants. One particular opportunity for education, at least popular in ultramarathon events, is the pre-race medical briefing, where medical directors and race staff have the ability to provide evidence-based guidelines to runners before the event commences.

Conclusion

Despite the well-documented, undesirable side-effects associated with NSAID use, there was a high incidence of use in our cohort of runners, particularly during a race in the ultramarathon group. More effort should be made to inform runners about the potential hazards of NSAID misuse and to offer alternatives to oral NSAIDs for minor pain relief. If necessary, NSAID use should be limited to a short-term regimen, taken after the injury, and for the intended purposes only.

Acknowledgements. The authors acknowledge Nathaniel Herr for assistance with data collection and William Grant for assistance with manuscript preparation.

Table 2. Acetaminophen and diclofenac use during the Desert RATS and ESM races

<table>
<thead>
<tr>
<th></th>
<th>Desert RATS</th>
<th>ESM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>During training</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>26%</td>
<td>15%</td>
</tr>
<tr>
<td>Topical diclofenac</td>
<td>19%</td>
<td>4%</td>
</tr>
<tr>
<td><strong>During competition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>11%</td>
<td>11%</td>
</tr>
<tr>
<td>Topical diclofenac</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>During recovery</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>11%</td>
<td>17%</td>
</tr>
<tr>
<td>Topical diclofenac</td>
<td>4%</td>
<td>4%</td>
</tr>
</tbody>
</table>

Desert RATS = Desert Race Across the Sand; ESM = Empire State Marathon.
References


